Financials data is unavailable for this security.
View more
Year on year AIM ImmunoTech Inc had net income fall 48.94% from a loss of 19.45m to a larger loss of 28.96m despite a 43.26% increase in revenues from 141.00k to 202.00k. An increase in the selling, general and administrative costs as a percentage of sales from 9,272.34% to 10,710.40% was a component in the falling net income despite rising revenues.
| Gross margin | 81.05% |
|---|---|
| Net profit margin | -12,594.21% |
| Operating margin | -14,695.26% |
| Return on assets | -115.46% |
|---|---|
| Return on equity | -192.79% |
| Return on investment | -179.69% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at AIM ImmunoTech Inc fell by 21.61m. Cash Flow from Financing totalled 485.00k or 240.10% of revenues. In addition the company used 21.27m for operations while cash used for investing totalled 832.00k.
| Cash flow per share | -0.4537 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.0496 |
|---|---|
| Tangible book value per share | 0.0065 |
More ▼
Balance sheet in USDView more
| Current ratio | 0.7495 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.9382 |
|---|---|
| Total debt/total capital | 0.484 |
More ▼
